|Acute Lymphoblastic Leukemia: Nursing Notes on Asparaginase Hypersensitivity and Silent Inactivation
Katelyn Oranges, MSN, CRNP, CPHON, and Joseph Sciasci, PharmD, BCOP
|Release Date: December 23, 2021
Expiration Date: December 23, 2022
Outcomes in acute lymphoblastic leukemia (ALL) have improved significantly for children over the past decades, due primarily in part to multi-agent chemotherapy. Asparaginases are a cornerstone of treatment for ALL, a critical component of many treatment protocols, and is used for remission induction and intensification treatment. Despite this success, hypersensitivity and silent inactivation remain a significant problem with treatment, so it is critical to rapidly identify when this occurs and know how to manage it. This activity will provide an interactive opportunity to test your knowledge and learn how to recognize, manage, and treat these complications.
This activity was previously presented as a webinar with live Q&A in December of 2021. Please note: If you participated in the live webinar, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Jazz Pharmaceuticals and Servier Pharmaceuticals, LLC.
|Begin, Earn CreditView Only, No Credit|